Capnography Devices Market Analysis

Capnography Devices Market Analysis

The hand-held segment in the capnography devices market was valued at USD 267 million in 2020 led by the numerous advantages offered by hand-held capnography instruments. These hand-held devices are manufactured to suit each patient’s condition and doctor’s specific preference to enable accurate movement of the instrument. These devices are easy to handle and highly portable to measure the carbon dioxide content of inspired and expired air. The battery-operated design of hand-held capnography devices provides the flexibility to accommodate both stationary & transport applications and mobile spot-checking. It delivers a broad range of movement and effortless positioning with a compact designing. Recently developed hand-held capnography devices come with a visual & audible alarm and side stream technology that accommodates both intubated & non-intubated patients.

The side stream segment accounted for 48% of the capnography devices market share in 2020 impelled by the use of side stream capnography instruments in a broad range of applications and the ability to perform capnography through a non-invasive & diverting method. Cost-effective operating, less maintenance, effectivity, and accuracy are some of the factors promoting the demand for side stream capnography devices. In addition, the development and commercialization of innovative side stream capnography instruments by several participants in the industry will augment the acceptance of these devices. Side stream capnography is widely used in non-intubated patients attributed to its non-invasive nature. It also delivers suitable quantitative bedside data related to ventilation-perfusion mismatching and uneven alveolar emptying.

The original equipment manufacturer (OEM) modules segment exceeded USD 234 million in 2020. An original equipment manufacturer (OEM) sells the components of capnography instruments to a firm so that it resells those devices to its specific consumers under its brand name. For instance, Covidien (Medtronic) has developed a Microstream MicroPod OEM module for its equipment manufacturer (OEM) partners to detect changes associated with ensuing respiratory failure.  Players operating in the market are emphasized to incorporate these OEM modules in their capnography instruments that aids healthcare facilities enhance patient safety by increasing access to capnography technology. Medtronic’s Microstream microMediCO? OEM module can be designed into a wider range of host configurations that measures etCO2, FiCO2, and respiration rate even in non-intubated patients.

The critical care segment is slated to reach USD 185 million by 2027 owing to the requirement of real-time monitoring and accurate measurement in the healthcare setting among critically ill patients. In the critical care unit, capnography devices deliver several benefits pertaining to monitoring of respiratory & cardiovascular function and airway management. Additionally, they diagnose displaced tracheostomy & tracheal tubes to detect inadvertent oesophageal intubation.

The hospitals end-use segment in the capnography devices market captured USD 285 million in 2020. The enhanced healthcare infrastructure of hospitals, surging number of multispecialty hospitals coupled with a growing number of surgeries for respiratory diseases is driving the segment revenue worldwide. Public and private organizations in developed regions are focusing on investing in the healthcare area, hence, the hospital segment will upsurge positively during the forecast timeframe. The easy availability of advanced technologies surges the demand for capnography devices among medical professionals in hospitals to simplify the patient monitoring by enabling clinicians to measure end-tidal CO2 and several vital signs with the same machine. This further allows pulmonologists to diagnose respiratory diseases efficiently. The adoption of innovative patient diagnostic systems to enhance patient care in hospitals is predicted to fuel the patient preference for hospitals.
 

U.S. dominated the North America capnography devices market in 2020 and is anticipated to cross USD 395 million by 2027 due to the growing prevalence of respiratory disorders. As stated by the Centers for Disease Control and Prevention, cigarette smoking is the major factor for lung cancer and in the U.S. cigarette smoking is linked to about 80% to 90% of lung cancer deaths. It is estimated that the impact of this disease will continue to rise in the following years attributed to the sedentary lifestyles and the acceptance of unhealthy habits. Moreover, as reported by the American Cancer Society, secondhand smoke is considered to cause over 7,000 deaths from lung cancer each year in the U.S. Furthermore, in 2019, the prevalence of asthma among adults age above 18 years was approximately 20,026,722 in the country. With the rising disease burden, the number of treatment procedures is also increasing that will further drive the capnography instruments demand in the coming years.